Collplant biotechnologies provides business updates and third quarter 2022 financial results

Partnership with abbvie to co-develop rhcollagen-based dermal and soft tissue fillers continues to advance according to plan co-developing 3d bioprinted human intestine model ("gut-on-a-chip") for drug discovery and personalized treatment of ulcerative colitis with tel-aviv university and sheba hospital 3d bioprinted regenerative breast implant program on track for q1 2023 readout of large animal study bioink platform expanded with recent launch of collink.3d™ 90 to offer additional functionality and performance benefits of biofabricated constructs strong balance sheet with cash and cash equivalents of $33m as of september 30, 2022 rehovot, israel , dec. 1, 2022 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended september 30, 2022 and provided an update on the company's business developments. "collplant made significant progress this quarter with our development partners to advance and diversify our product portfolio, which is targeting large commercial opportunities in both existing and new markets, including medical aesthetics and personalized medicine," said yehiel tal, collplant's ceo.
CLGN Ratings Summary
CLGN Quant Ranking